An investigative history of the scandal-plagued company shines a light on a health care industry riddled with corruption and ...

Johnson had stopped on the side of the road ... he’d also been experiencing personal struggles. Diagnosed with depression and bipolar, the recovering addict often beat himself up about his ...

BofA Securities 2025 Healthcare Conference May 13, 2025 1:40 PM ETCompany ParticipantsJohn Reed - Executive Vice ...

For example, Johnson & Johnson has already launched a new drug that claims to fix ‘errant’ brain structures for tackling depression: esketamine (trade name Spravato). The company claims ...

Early research suggests semen quality is a biomarker for general health – and now swathes of men are getting tested in the ...

Johnson & Johnson has been noted for its conservative ... adding the schizophrenia and bipolar depression treatment CAPLYTA to its portfolio. The company faces some headwinds in 2025, including ...

Johnson also says there may be some overlap in the body systems influenced by antidepressants and probiotics. “The ...

The esketamine nasal spray – sold as Spravato by Johnson & Johnson – is the first new class of depression drug subsidised by the Pharmaceutical Benefits Scheme in more than 30 years.

People who had connected with Bailey Koch and her family's story mourned the death of a mental health advocate and ...

The Johnson County Board of County Commissioners ... clients around the clock who may be experiencing suicidal thoughts, depression, or substance use issues. Medicaid revenue will help fund ...

The sweeping tax bill failed to clear a key hurdle, as hardline Republicans wanting deeper cuts blocked it, a rare ...